Novo Nordisk's Options: A Look at What the Big Money is Thinking
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...
Down 19% in 1 Day, Is Novo Nordisk Stock Still a Buy?
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...
What Analysts Are Saying About Novo Nordisk Stock
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...
3 Cheap Stocks: Nike, Teva, And Novo Nordisk
From a historical perspective, Nike (NKE) is a cheap stock to consider. The retailer, best known for its athletic shoes, lost ...
Pharmaceutical Technology2d
Ziltivekimab by Novo Nordisk for Myocardial Infarction: Likelihood of Approval
Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Myocardial Infarction.
In weight loss battle, Novo and Lilly face growing offensive from licensed copies
As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...
Pharmaceutical Technology3d
Liraglutide by Novo Nordisk for Alzheimer’s Disease: Likelihood of Approval
Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't ...
Business Insider13d
Novo Nordisk’s CagriSema Shows Promising Results in Obesity Trial
The company is committed to addressing serious chronic diseases, particularly in the diabetes sector, through scientific advancements and widespread access to its pharmaceuticals. Novo Nordisk ...